This article is more than 5 years old. Information may no longer be current.

Can-Fite BioPharma announces positive results for phase 2 study of dry eye drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PETACH TIKVA, Israel — Can-Fite BioPharma's phase 2 clinical trial of an investigational oral treatment for dry eye syndrome has met the primary efficacy endpoint of relieving signs and symptoms of related ocular surface inflammation, the company announced in a press release.

The drug, called CF101, targets A3 adenosine receptors on the surface of pathologic cells.

In the masked study, 80 patients with moderate to severe dry eye were randomly assigned to receive either 1 mg of oral CF101 or placebo monotherapy for 12 weeks. According to fluorescein staining measurements, patients who received CF101 experienced a statistically significant improvement in superficial punctate keratitis. In addition, the compound was safe and well-tolerated.

The investigators also found that patients who received oral CF101 demonstrated a decrease in IOP, suggesting that adenosine A3 agonists may show benefit for treating glaucoma, the release said.